newsfilter
← Latest News
GlobeNewswire·

Hengrui Pharma and Braveheart Bio Present Data from 52-Week Open-Label Extension of Phase 2 Study of HRS/BHB-1893 in Obstructive Hypertrophic Cardiomyopathy at American Heart Association Scientific Sessions 2026

BRVE
  • Hengrui Pharma & Braveheart Bio presented 52-week open-label extension data for HRS/BHB-1893 in 42 patients with obstructive hypertrophic cardiomyopathy (oHCM) at the AHA Scientific Sessions 2026.
  • Peak oxygen uptake (pVO2) increased by a mean of 2.7 mL/kg/min & Kansas City Cardiomyopathy Questionnaire scores rose by 17.3 points at Week 52.
  • 79% of patients achieved a Valsalva LVOT gradient below 30 mmHg at Week 52, with 90% achieving this at one or more visits during treatment.
  • 57% of patients remained on the 40 mg BID starting dose at study end, supporting a simplified dosing regimen.
  • Extended treatment demonstrated durable LVOT gradient reduction with attenuated rebound in gradients & NT-proBNP compared to the post-washout period after 12 weeks.
  • HRS/BHB-1893 was generally well tolerated with no severe or serious adverse events & no discontinuations due to safety concerns.
  • Preclinical & non-obstructive HCM (nHCM) data suggest the drug improves diastolic function while preserving systolic function via reduced actomyosin cross-bridge activity.
  • In nHCM patients, 59% exceeded the normal threshold for septal e' & 57% for lateral e' after 12 weeks of treatment.
  • Braveheart Bio announced a planned fixed-dose Phase 2b study in oHCM (TRUEHEART-HCM) & will host an investor webcast on November 6, 2026.
  • The data indicate potential for reverse remodeling & the ability to address underlying pathophysiology across both oHCM & nHCM forms.
Company
Braveheart Bio, Inc.
Keywords
Nasdaq:BRVE, Braveheart Bio, Inc., biotechnology, cardiology, cardiomyopathy, pharmaceuticals